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hypothesis: Blood group antibodies are natural antibodies that develop early in life in 
response to cross-reactive environmental antigens in the absence of antigen encounter. 
Even later in life structural similarities in saccharide composition between environmental 
antigens such as bacterial polysaccharides and blood group A/B antigens could lead to 
changes in serum levels, IgM/IgG isotype, and affinity maturation of blood group anti-
A/B antibodies. We addressed the question whether immunization with pneumococcal 
polysaccharide (PnP) vaccine Pneumo 23 Vaccine “Pasteur Merieux” (Pn23) could have 
such an effect in patients with type I diabetes mellitus (DM I), an autoimmune disease 
where an aberrant immune response to microbial antigens likely plays a role.
Methods: Anti-PnP IgM and IgG responses were determined by ELISA, and the 
DiaMed-ID Micro Typing System was used to screen anti-A/B antibody titer before and 
after Pn23 immunization in 28 healthy individuals and 16 patients with DM I. In addition, 
surface plasmon resonance (SPR) technology using the Biacore® device and a synthetic 
blood group A/B trisaccharide as the antigen was applied to investigate IgM and IgG 
anti-A/B antibodies and to measure antibody binding dynamics.
results: All healthy individuals and DM I patients responded with anti-PnP IgM and IgG 
antibody production 4–6 weeks after Pn23 immunization, while no increase in blood 
group anti-A/B antibody titer was observed when measured by the DiaMed-ID Micro 
Typing System. Interestingly, isotype-specific testing by SPR technology revealed an 
increase in blood group anti-A/B IgG, but not IgM, following Pn23 immunization in both 
patients and controls. No change in binding characteristics of blood group anti-A/B 
antibodies could be detected following Pn23 vaccination, supporting the assumption of 
an increase in IgG antibody titer with no or very little affinity maturation.
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inTrODUcTiOn
Natural antibodies are produced in the absence of overt exter-
nal antigenic stimulation early in life in all healthy individuals 
with a functional immune system, presumably as a product 
of germline gene segment assembly (1). Therefore, they show 
low affinity to many microbial pathogens and certain cross-
reactivity, even to some self-antigens (1–4). Antibodies to 
carbohydrate epitopes share certain characteristics with natural 
antibodies, e.g., the absence of extensive class switching and 
affinity maturation due to absent T-cell help (5). Isoagglutinins, 
i.e., antibodies against carbohydrate epitopes that form the AB0 
antigens on red blood cells (RBCs), are considered prototypic 
natural antibodies that were shown to be compromised in 
patients with immunodeficiency (1, 4, 6). Their appearance 
can be explained by inapparent stimulation particularly from 
intestinal bacteria because antigens cross-reactive with blood 
group polysaccharides are widely distributed in the environ-
ment (1,  7,  8). Natural anti-ABO antibodies have long been 
considered to be predominantly of the IgM isotype, but antibod-
ies of the IgG isotype are also produced, especially later in life, 
e.g., after alloimmunization in pregnancy or ABO-incompatible 
blood transfusions (1). In the case of ABO blood groups, 
individuals with blood group A develop an immune response 
to B-like antigens of microorganisms and environmental 
antigens like plants containing these epitopes (1, 9). B blood 
group individuals develop anti-A antibodies, O blood group 
individuals produce both anti-A and anti-B antibodies, while 
AB blood group subjects have neither anti-A nor anti-B because 
they express both antigens on their RBCs.
The human ABO blood group antigens are oligosaccharide 
moieties formed on precursor backbones by glycosyltrans-
ferases (4, 9, 10). Blood group O individuals have carbohydrate 
structures named H-antigen terminated in the sequence alpha-
Fuc(1,2)Gal. The blood group A antigen is then formed from the 
H-antigen by an N-acetylgalactosaminyltransferase that uses a 
UDP-N-acetylgalactosamine (GalNAc) donor, and the blood 
group B antigen is formed by a galactosyltransferase that uses 
a UDP-galactose (Gal) donor to convert the H-antigen (4). The 
human A and B blood group antigens differ from each other 
only in the substitution of an acetamino for a hydroxyl group 
on the terminal saccharide residue, and this substitution can 
be differentially recognized by specific antibodies (1, 4, 11, 12). 
Interindividual variations in the titer of anti-blood group ABO 
antibodies exist, representing modulation of the production of 
these natural antibodies in response to cross-reactive environ-
mental antigens, e.g., through immunization (1). B cells could 
thus recognize shared carbohydrate epitopes due to structural 
similarities in saccharide composition, e.g., between microbial 
polysaccharides (PnPs) and blood group A/B antigens, which 
could also have an effect on blood group anti-A/B specific 
antibody production after PnP-immunization. Previous findings 
indicate shared epitopes between blood group oligosaccharides 
and pneumococcal capsular polysaccharides, as antibodies cross-
reacting with human erythrocytes and pneumococcal antigens 
have been described (7). Furthermore, it was shown that cross-
reactive carbohydrate determinants (CCDs) contained in blood 
group antigens and microbial polysaccharides can be targeted by 
immunoglobulins of different isotypes, in particular by IgE, but 
also by IgG antibodies (13).
In addition to their role as a first line of defense against infec-
tion, natural antibodies have been shown to play an important 
role in the initiation of autoimmunity (2, 8, 14–16). Natural 
antibodies reacting with self-antigens were initially considered 
to represent breakdown of tolerance, thus functioning as a tem-
plate for the generation of pathogenic autoantibodies produced 
through a process of clonal selection, somatic hypermutation, 
and class switching driven by antigen (14). More recently, these 
antibodies have been attributed an additional role in the preven-
tion of autoimmune disease, e.g., by inhibiting activation of the 
adaptive immune system by molecules released from apoptotic 
cells that could facilitate autoimmune events (15, 16). Formation 
of natural antibodies with high cross-reactivity could be regu-
lated differently in healthy individuals as compared to individu-
als with an autoimmune disease such as type 1 diabetes mellitus 
(DM I) known to present with abnormalities in antibody forma-
tion (17). In addition to high-risk HLA genes, environmental 
factors are thought to play an important role in the pathogenesis 
of DM I, such as pancreatic virus infection, T  cell-mediated 
and autoantibody-mediated molecular mimicry, and bystander 
activation of autoreactive lymphocytes by proinflammatory 
cytokines derived from dendritic cells activated by infection-
related stimuli through innate pattern recognition receptors 
such as TLR (18–21). A single causative infectious agent for DM I 
autoimmunity has not been found, pointing toward the possibil-
ity that different infectious agents are capable of non-specifically 
enhancing the likelihood of autoimmunity. In addition to virus 
infection (19, 20), bacterial infection might play a role in the 
development of DM I, as antibodies against mycobacterial and 
proinsulin epitopes (22) as well as beta cell antigens (23) show 
conclusion: The study provides evidence for epitope sharing between pneumococcal 
polysaccharides and blood group ABO antigens, which leads to a booster of blood 
group anti-A/B antibodies of the IgG isotype after Pn23 immunization in healthy individ-
uals. Manifest autoimmunity such as present in DM I patients has no additional effect on 
the cross-reactive antibody response against pneumococcal polysaccharides and blood 
group antigens.
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group a/B antibodies, surface plasmon resonance, isoagglutinins, natural antibodies
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cross-reactivity in children with new onset DM I. While human 
IDDM autoantigens are typically T-dependent protein antigens, 
microbial polysaccharides have been shown to modulate the 
autoimmune response leading to DM1 (24). Innate signaling 
via TLR and MyD88, pathways critical for T cell-independent 
(TI) immune defense (25), can reverse anergy in autoreactive 
B cells, suggesting that environmental factors associated with 
bacterial infection and inflammation may alter tolerance (26). 
Concerns that vaccination might lead to the development of 
autoimmune disease such as DM I have been raised (27), which 
could also relate to polysaccharide vaccines, as molecular 
mimicry in bacterial polysaccharide components is capable of 
inducing autoreactive antibodies, e.g., against some blood group 
antigens or neuronal gangliosides (28). In the present study, 
we investigated whether vaccination with Pneumo 23 Vaccine 
“Pasteur Merieux” (Pn23) has an effect on blood group ABO 
antibodies in healthy individuals and in patients with DM I. To 
screen for blood group anti-A/B antibodies, we used the com-
mercially available DiaMed-ID Micro Typing System based on 
erythrocyte agglutination (6). To measure blood group-specific 
anti-A/B antibodies in healthy individuals and in patients with 
DM I in an isotype-specific manner, we used surface plasmon 
resonance (SPR) technology and synthetic A/B trisaccharides 
bound via amine-coupling to the CM5 chip (6, 11, 12). SPR 
using blood group-specific A/B synthetic trisaccharides is the 
ideal technology to investigate a potential IgM to IgG isotype 
shift and to investigate changes in binding characteristics of the 
relevant blood group anti-A/B antibodies under near to physi-
ological conditions in real time.
MaTerials anD MeThODs
Vaccination of healthy individuals and 
Patients with Type i DM and Measurement 
of anti-PnPs antibodies
During a clinical study published previously (17), healthy 
individuals (n = 39) and patients with type I DM (n = 20) were 
immunized with the PnPs vaccine Pn23 (a 23-valent vaccine 
containing pneumococcal capsular polysaccharide serotypes 1, 2, 
3, 4, 5, 6B, 7, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 
20, 22F, 23F, and 33F, Pasteur Merieux Connaught, Lyon, France) 
after informed consent was obtained (17, 29). Type I DM patients 
were, on average, 16 ± 7.4 years (SD) at the onset of disease, and 
at that time they tested positive for GAD autoantibodies. Age at 
initiation of the vaccination study was 31.7 ± 8.8 years (SD). For a 
detailed description of patients and controls, see Ref. (17). Blood 
samples were drawn 4–6  weeks after vaccination, the serum 
was immediately separated from the cellular blood component, 
dispensed into 500  μl aliquots, and stored until analysis in a 
freezer at −20°C. For this follow-up study, serum aliquots stored 
at −20°C were still available from 28 healthy controls and 16 DM 
I patients; selection of this subset of the previous study was only 
because no more serum was available from the other controls and 
DM I patients of the original study. Anti-PnPs antibodies were 
determined by a home-made ELISA detecting all serotypes as 
previously described (17, 30).
Determination of anti-a/B antibody Titers 
by the DiaMed-iD Micro Typing system
Titers of blood group anti-A and anti-B antibodies were deter-
mined by the DiaMed-ID Micro Typing System (Bio-Rad Lab. 
Inc., Hercules, CA, USA) used according to the manufacturer’s 
protocol. The ID-Card 50520 (NaCl) was used to measure IgM, 
while the ID-Card 50531 [LISS/Coombs containing poly-
specific anti-human gamma globulin (AHG) serum] was used 
to determine IgG in addition to IgM. The serum samples were 
serially twofold diluted with 0.9% saline solution starting with 
500 μl serum and 500 μl saline solutions. Also, 25 μl of each 
dilution were pipetted into a single column of the microtube 
gel card, and 50  μl of DiaMed-ID-DiaCell ABO/I-II test cell 
suspensions A1 or B (Bio-Rad Lab.) was added. ID-Card 50520 
(NaCl) cards were incubated at room temperature for 15 min, 
the ID-Cards (LISS/Coombs) at 37°C, and thereafter centrifuged 
in a DiaMed-ID-Centrifuge 24 S for 10 min at 910 rpm. Results 
were read immediately after centrifugation and were subdivided 
into positive and negative results. The titer that led to visible 
agglutination of erythrocytes dispersed in the gel was selected 
positive. In an individual with blood group O, both anti-A and 
anti-B antibody titers were used for statistical analysis, while in 
an individual with blood group A, only anti-B antibody titers, 
and in an individual with blood group B, only anti-A antibody 
titers were used for statistical analysis; none of the study indi-
viduals had blood group AB.
Determination of anti-a/B antibodies 
by surface Plasmon resonance
The erythrocyte aggregation assays based on the DiaMed-ID 
Micro Typing System are semiquantitative assays that cannot 
determine in an isotype-specific way a subtle increase of anti-A/B 
IgG and/or IgM antibodies against blood group A/B antigens. 
Therefore, we used SPR to measure anti-A/B antibodies as previ-
ously described (6, 11, 12). Amine-labeled blood group A and 
B trisaccharides (Dextra Laboratories Ltd., Reading, UK) were 
immobilized on two-channel sensor chips CM5 (General Electric 
Health Care, Freiburg, Germany) using standard protocols (31, 
32). In brief, the CM5 sensor chip surface was activated with 
100 μl 0.05 mol/l N-hydroxy-succinimide and 0.2 mol/l N-ethyl-
N′-dimethylamino-propylcarbodiimide injected into the buffer 
stream of HBS-EP (0.01 mol/l HEPES buffer, pH 7.4, containing 
0.15 mol/l NaCl, 3 mmol/l EDTA, and 0.005% surfactant P20) as 
described previously (6). The buffer stream was passed through 
FC-1 and FC-2 of the two-channel Biacore® X instrument (GE 
Health Care) at a flow rate of 5 μl/min for 20 min. Subsequently, 
15 μl of a blood group A/B trisaccharide amine derivative solu-
tion at a concentration of 1 mg/ml, prepared with borate (pH 8.5), 
was injected into the buffer stream and passed through FC-1 at 
a flow rate of 5 μl/min and was halted after injection of 7 μl for 
2 h; FC-2 served as a blank control. Residual active ester groups 
on the sensor surface were then deactivated by injecting 100 μl 
of 1  mol/l ethanolamine–HCl (pH 8.5) into the buffer stream 
and passing it through FC-1 and FC-2, and by passing the buffer 
stream through the cell until a stable baseline was achieved. To 
measure anti-blood group A/B antibodies, serum was diluted by 
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half with the HBS-EP, and 100 μl of the diluted plasma samples 
were passed through FC-1 and FC-2 at a flow rate of 20 μl/min for 
5-min duration. When the association phase was finished, bind-
ing of antibody was recorded and is expressed as resonance units 
(RU at “stability” in Figure 1, corresponding to RUt0 in Figure 2, 
panel 3). After each measurement, the antibodies bound to the 
blood group trisaccharides were removed with 50 μl of 50 mmol/l 
NaOH buffer at a flow rate of 60 μl/min for 50  s and the chip 
regenerated to reach the same baseline as prior to the measure-
ment. The amounts of anti-A/B antibody that associated with 
the blood group A/B trisaccharide antigen immobilized on the 
sensor chip surface were obtained by subtracting the FC-2 value 
from the FC-1 value.
Alternatively, a four channel Biacore® T200 device (kindly 
provided by Florian Koelle, GE Health Care) was used, which 
enabled us to measure both anti-A and anti-B antibodies on 
one chip surface (CM5-chip) at the same time. The amount of 
trisaccharides and the coupling procedure remained similar to 
the two-channel system used previously, except the contact time 
was adapted to 600 s and the flow rate to 10 μl/min. Flow cell 
one (FC-1) and three (FC-3) were immobilized without trisac-
charides and served as blank during binding analysis. FC-2 was 
immobilized with 1  mg/ml blood group A trisaccharide and 
FC-4 with 1  mg/ml blood group B trisaccharide. For binding 
analysis, serum was diluted by half with HBS-EP and injected in 
FC-2 and FC-4 for 180 s at a flow rate of 10 μl/min. The flow-path 
was 2–1 and 4–3. To determine IgM and IgG levels of A- and 
B-bound antibodies, anti-human IgG Abs [polyclonal aHIgG 
(γ-chain), Sigma-Aldrich, St. Louis, MO, USA] and anti-human 
IgM [polyclonal aHIgM (μ-chain), Sigma-Aldrich, St. Louis, 
MO, USA] were injected for 180  s at a flow rate of 10 μl/min 
directly after the serum sample. For measurement of anti-A/B 
antibodies RU at report point “stability” (see Figure  1, corre-
sponding to RUt0 in Figure 2, panel 3) and for levels of IgM/IgG 
anti-A/B antibodies levels at report point “enhance_level” (see 
Figure 1) relative to baseline were recorded. After determina-
tion of levels of IgM and IgG anti-A/B antibodies, the chip was 
regenerated twice with 50 mmol NaOH for 30 s at a flow rate 
of 10 μl/min with a stabilization period of 5 s after the second 
regeneration to reach the same baseline as prior to the measure-
ment. For kinetic measurement, an association time of 200 s and 
dissociation time of 800  s was chosen. Dissociation of bound 
anti-A/B antibodies over time as a semiquantitative correlate for 
the strength of antibody binding was calculated according to the 
following formula: % dissociation =  100 −  [RU at t1 (800  s)/
RU at t0 (200 s)] × 100 (see Figure 2, panel 3 as an example for 
measurement of RU at t0 and at t1). To compute an affinity con-
stant KD the concentration of IgG antibodies in microgram per 
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Panel (1) different concentrations of monoclonal anti-A IgG (internal control) were injected to correlate response units to micrograms per milliliter, (2) anti-A IgG levels 
in human serum were determined utilizing a second injection of anti-IgG (Sigma), (3) different dilutions of human serum were measured without addition of second 
step reagent, and binding curves were recorded for a total of 1,200 s, (4) an estimate of KD was calculated using the BIAevaluation Software (GE Healthcare) with 
input of the concentrations of anti-A IgG determined in steps (2) and (3) as described in Section “Materials and Methods.”
FigUre 2 | continued
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milliliter must be known, thus RUs for different concentrations 
of monoclonal anti-A/B IgG (clone 9A, Abcam, Cambridge, 
MA, USA; clone NaM87-1F6, BD Pharmingen, San Jose, CA, 
USA) were measured (Figure  2, panel 1). This enabled us to 
correlate an increase in response units derived from anti-A/B 
IgG measurements in patient serum with microgram per mil-
liliter of anti-A/B IgG antibody by regression analysis in order to 
calculate the respective concentration of IgG anti-A/B (Figure 2, 
panel 2). Subsequently two dilutions of patient serum – one of 
them diluted 1:2 – and a blank were measured (Figure 2, panel 
3), and the resulting binding curves were used to calculate KD 
(computed as KD = Koff/Kon) with the BIAevaluation® software 
from GE Healthcare. To fit the association/dissociation curve, 
a 1:1 binding model was chosen. The molecular weight of the 
analyte was assumed to be 150,000 Da (IgG). To assess the qual-
ity of the calculations, controls within the software were used. 
No external calculations were performed nor parameters added. 
Furthermore, as an internal control to test before each measure-
ment was started, anti-blood group A or B IgM mAbs (anti-A 
murine monoclonal Abs clone MH04 and A3D3, anti-B murine 
monoclonal Abs clone NB1.19, NB10.5A5, and NB10.3B4, 
Ortho-Clinical Diagnostics, Neckargemünd, Germany), and 
anti-blood group A IgG mAb (clone 9A, Abcam, Cambridge, 
MA, USA; clone NaM87-1F6, BD Pharmingen, San Jose, CA, 
USA) were used to guarantee optimal chip performance and full 
recovery. For statistical analysis, both anti-A and anti-B antibody 
titers (RU) were used in an individual with blood group O, while 
in an individual with blood group A, only anti-B antibody titers, 
and in an individual with blood group B, only anti-A antibody 
titers were used for statistical analysis; none of the individuals in 
this study had blood group AB.
statistical analysis
Statistically significant differences between study groups were 
calculated using the non-parametric two-tailed Mann–Whitney 
U-test. Results are depicted using box plot diagrams, with the 
median represented by a cross, the interquartile range (IQR) rep-
resented by the box, and 5- and 95-percentile values represented 
by the whiskers.
resUlTs
anti-PnPs response in healthy individuals 
and in Patients with Type i DM after 
Pneumovax®23 immunization
The anti-PnPs antibody response prior and 4–6 weeks after immu-
nization with the unconjugated PnPs vaccine Pn23, a 23-valent 
vaccine, was determined by ELISA in an isotype-specific manner 
in 28 healthy individuals and 16 patients with DM I. All healthy 
individuals included in this study showed a significant IgM 
(Figure 3A) and IgG (Figure 3B) anti-PnPs antibody response 
following vaccination. The results confirm previous findings in 
patients with type I DM (17) showing a normal antibody response 
to unconjugated pneumococcal polysaccharide, which is likely TI, 
while primary antibody responses to T-cell-dependent antigens 
are impaired (17).
increase in Blood group igg anti-a/B 
antibodies in healthy individuals and in 
Patients with Type i DM after 
Pneumovax®23 immunization as 
Determined with the Biacore® Device
To address whether immunization with Pn23 has an effect on 
blood group anti-A/B antibodies in patients with DM-type 
I as compared to healthy individuals, we first determined 
antibody titers in the DiaMed-ID Micro Typing System, using 
the ID-Card 50520 (NaCl) as well as the ID-Card 50531 (LISS/
Coombs containing poly-specific AHG serum) to determine 
IgG in addition to IgM anti-A/B antibodies. We could observe 
no difference in blood group anti-A/B antibody titer prior and 
post immunization with Pn23 in both, healthy individuals and 
patients with DM-type I when the assay used was based upon 
erythrocyte aggregation in physiological NaCl (direct aggluti-
nation test, Figure 4A) or in the presence of anti-IgG Coombs 
serum (indirect agglutination test, Figure 4B). Interestingly, in a 
considerable percentage of study individuals of both groups (up 
to approximately 25%) the A/B isoagglutinin titers were lower 
than 1:4 in both agglutination systems, thus confirming previous 
findings of a relatively low sensitivity of the agglutination system 
to detect low isoagglutinin titers (6). To increase sensitivity, SPR 
technology was applied to further analyze anti-A/B antibod-
ies, thus allowing real-time analysis of molecular interactions 
between antibodies and the isolated blood group trisaccharide 
antigen without molecular labeling leaving the structure of 
both molecules intact (6, 32). With this technology, biologically 
relevant antibody–antigen interactions can be assessed both 
quantitatively and qualitatively, as the carbohydrate antigens 
are presented in a physiological manner (11, 12, 31). Kinetics 
and affinity were investigated by analyzing the time curve and 
level of binding and concentration of anti-A/B antibodies in 
the sample by measuring mass binding, which further allowed 
the determination of the binding forces. The comparison of 
the response on the active and control surface allowed for the 
subtraction of bulk effects associated with buffer changes and 
for the high serum concentration with its mass binding, thus 
enabling the calculation of specific binding. Using SPR analysis, 
we found specific anti-A/B antibody binding to the respec-
tive blood group A/B trisaccharides in all individuals tested 
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FigUre 3 | igM/igg antibody response to pneumococcal polysaccharides after immunization with Pn23 vaccine. Healthy individuals (n = 28) and 
patients with type I DM (n = 16) were immunized with the PnPs vaccine Pneumo 23 Vaccine “Pasteur Merieux” (Pn23), and blood samples were drawn 4–6 weeks 
after vaccination. Antibodies against pneumococcal polysaccharides (anti-PnPs) were determined by ELISA as described in Section “Materials and Methods” and 
presented as IgM–Pn23-antibody response (a) or IgG–Pn23-antibody response (B). Results are depicted using box plot diagrams, with the median represented by 
a cross, the interquartile range (IQR) represented by the box, and 5- and 95-percentile values represented by the whiskers; statistically significant differences 
between study groups were calculated using the non-parametric two-tailed Mann–Whitney U-test.
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(Figure 4C), as has also been described previously for individu-
als with intact antibody responsiveness (6, 12). For all probes, a 
high association rate constant for the interaction and the use of 
a high ligand density on the sensor chip surface was found that 
promoted the mass transport limitation. As reference analyte 
with a known concentration, commercially available blood 
group anti-A or -B antibodies of IgM and blood group anti-A 
IgG were used (Figure 2, panel 1 shows monoclonal anti-A IgG 
as an example). For the example shown in Figure 2, panel 1, a 
sensor response of 1,000 RU corresponded to a shift of 0.1° in 
the SPR angle, which in turn correlates to approximately 16 μg/ml 
of anti-A IgG injected. Since the individuals selected for deter-
mination of KD [one healthy control (Ind1) and one DM I patient 
(Ind2) as well as a control individual not vaccinated] contained 
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FigUre 4 | analysis of blood group anti-a and anti-B isoagglutinin binding to a and B trisaccharide antigen in real time by surface plasmon 
resonance (sPr) technology.  
 (Continued)
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Serum samples of healthy individuals (n = 28) and patients with type I DM (n = 16) were serially twofold diluted with 0.9% saline solution and blood group anti-A 
and/or anti-B IgM (a) were determined by ID-Card 50520 (NaCl), while the ID-Card 50531 (LISS/Coombs) was used to determine IgG and IgM isoagglutinins (B). 
The titer that led to visible agglutination of erythrocytes dispersed in the gel was selected positive. Alternatively (c), serum samples diluted in HES-EP buffer (1:2) 
were injected over either the blood group A or blood group B trisaccharide-coupled CM5 sensor chip. Binding kinetics, i.e., association and dissociation were 
recorded as sensorgrams in resonance units (RU) against time in FC-I and FC-II, and the amount of anti-A/B antibody that associated with the blood group A/B 
trisaccharide antigen immobilized on the sensor chip surface was obtained by subtracting the FC-II value from the FC-I value and is given as resonance units (RU). 
Results are depicted using box plot diagrams, with the median represented by a cross, the interquartile range (IQR) represented by the box, and 5- and 
95-percentile values represented by the whiskers; no statistically significant differences were found between study groups as calculated using the non-parametric 
two-tailed Mann–Whitney U-test.
FigUre 4 | continued
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sufficient amounts of anti-A IgG for affinity analysis with very 
low to undetectable anti-A IgM, titration was only performed 
for IgG anti-A/B antibody. Of note, SPR technology is capable 
to detect anti-A/B antibodies with values of 50–180 RU in serum 
samples where the microtube column assay showed no erythro-
cyte aggregation. Even with this sensitive detection system, no 
change in isoagglutinin titers was found following vaccination 
with 23-valent PnPs, neither in healthy individuals nor in DM1 
patients (Figure 4C).
Using the DiaMed-ID Micro Typing System in the direct and 
indirect agglutination assay as well as SPR technology under close 
to physiological conditions, both IgM- and IgG-antibodies were 
measured simultaneously, without discrimination between IgM 
and IgG response. To examine a possible booster effect of Pn23 
vaccination on IgG anti-A/B antibodies only we applied isotype-
specific second step antibodies to discriminate between blood 
group anti-A/B IgM and IgG antibodies. This system enabled us 
to detect an induction of blood group anti-A/B IgG (Figure 5B) 
but not IgM (Figure  5A) antibodies after immunization of 
healthy individuals with Pn23, an antibody response resembling 
a secondary/booster response. Interestingly, patients with type I 
DM showed a comparable induction of IgG isoagglutinins after 
immunization with Pn23 (Figure 5B), in agreement with their 
intact antibody responsiveness to pneumococcal polysaccharide, 
a T-independent antigen, while a significant impairment in 
primary antibody response to vaccination with T-cell-dependent 
antigens such as hepatitis A virus and diphtheria toxoid was 
described previously (17).
Determination of Binding characteristics 
of anti-a/B antibodies after 
Pneumovax®23 immunization
To measure whether the induction of IgG-A/B antibodies 
observed after Pn23 immunization was accompanied by 
changes in binding characteristics of the blood group anti-A 
antibodies, as would be the case for a T-dependent IgG-booster 
response, we analyzed the binding dynamics of the anti-A/B 
antibodies as described above (Figure  2). We found no sub-
stantial change in the percentage of dissociation (Figure 6A) 
or the estimate of the affinity constant (KD, Figure 6B) of blood 
group-specific anti-A antibodies following pneumococcal vac-
cination, as calculated by BIAevaluation® software from GE 
Healthcare. For estimation of the affinity constant KD, healthy 
individuals and patients with type I DM were selected that 
had initially high anti-A-antibody titers (>1:256 or >700 RU), 
associated with high anti-A IgG and low to undetectable anti-A 
IgM antibody levels. Only three healthy individuals and two 
patients with type I DM fulfilled this criterion. As shown in 
Figure 6 (depicting results from one healthy individual, Ind1 
and one DM I patient, Ind2), our study gives evidence that 
immunization with Pn23 induces an increase in IgG anti-A/B 
antibody titers but has no effect on binding characteristics of 
blood group anti-A/B IgG antibodies, neither in the healthy 
individuals nor in the patients tested.
DiscUssiOn
Based on previous findings (7, 13) it was our hypothesis that 
structural similarities in saccharide composition between 
pneumococcal polysaccharides and blood group A/B saccha-
ride antigens could lead to production of cross-reactive blood 
group anti-A/B antibodies after immunization with capsular 
polysaccharide vaccines, because B cells could recognize shared 
carbohydrate epitopes (2, 8, 10, 33, 34). In the current study, we 
indeed show that immunization with Pn23 vaccine is followed by 
induction of blood group anti-A/B antibodies of the IgG isotype 
in healthy individuals. Anti-A/B IgG antibodies could only be 
demonstrated when SPR technology using the Biacore® device 
was applied, while conventional technology employing eryth-
rocyte aggregation assays using the DiaMed-ID Micro Typing 
System were unable to detect this side effect of Pn23 vaccination. 
Apparently, the increased sensitivity of SPR technology as com-
pared to conventional erythrocyte agglutination assays as well as 
the near to physiological conditions of the molecular interaction 
between antibodies and the specific blood group trisaccharide 
antigen enabled us to detect the stimulation of small amounts of 
cross-reactive IgG antibodies (11, 12, 31, 32). A previous study 
described an alternative approach to measure isoagglutinins in 
an isotype-specific and sensitive manner by using synthetic blood 
group saccharides in ELISA and showed cross-reactivity between 
alpha-Gal and blood group B oligosaccharide (13). The increase 
in blood group anti-A/B IgG isotype response observed in our 
study provides additional evidence for a limited cross-reactivity 
between PnPs antigens and the carbohydrate moieties of blood 
group A/B trisaccharides. Whether the observed induction of 
IgG antibodies cross-reacting with A/B blood group antigens 
is of clinical relevance in healthy individuals remains to be 
determined but is unlikely due to the relatively small increase 
(approximately twofold) observed. Patients with type I DM 
0100
200
300
400
500
600
700
controls before
vaccination
controls after
vaccination
DM1 before
vaccination
DM1 after
vaccination
an
ti-
A
/B
 Ig
M
 (R
U
)
0
100
200
300
400
500
600
700
800
controls before
vaccination
controls after
vaccination
DM1 before
vaccination
DM1 after
vaccination
an
ti-
A
/B
 Ig
G
 (R
U
)
p=0.0172 p=0.0198
A
B
FigUre 5 | increase in blood group igg anti-a/B antibodies in healthy individuals and in patients with type i DM after immunization with Pn23 
vaccine as determined with the Biacore® device. To determine IgM (a) and IgG (B) anti-A/B antibodies in healthy individuals and patients with type I DM prior 
and post immunization with Pneumo 23 Vaccine “Pasteur Merieux” (Pn23), an anti-human IgM mAb (a) or anti-human IgG Abs (B) were applied as the second step 
reagents as described in Section “Materials and Methods.” Results are depicted using box plot diagrams, with the median represented by a cross, the interquartile 
range (IQR) represented by the box, and 5- and 95-percentile values represented by the whiskers; statistically significant differences between study groups were 
calculated using the non-parametric two-tailed Mann–Whitney U-test. For the IgM antibody response, no statistically significant differences were found between 
study groups.
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displayed a comparable cross-reactive IgG antibody response 
against blood group antigens following Pn23 vaccination, 
although these patients present an autoimmune disease with 
profound immunological dysregulation (17, 18). Interestingly, 
cross-reactive IgM antibodies were not inducible, neither in 
DM1 patients nor in controls. This is characteristic of a booster 
response effecting IgG responses only and contrary to the effect of 
immunization with a conventional polysaccharide antigen such 
as PnPs inducing both anti-PnPs IgM and IgG antibody responses 
following booster vaccination (Figure 3).
An additional benefit of the SPR-based technology employed 
in this study is the capability for real-time measurements of 
affinity of antibody–antigen interactions without the use of 
molecular labeling, leaving the structure of both interacting 
molecules intact (11, 12, 32). Calculations of KD as performed 
in our study using human serum as a sample can only be 
an estimate for the true affinity of a given antibody since we 
are dealing with a variety of polyclonal antibodies of differ-
ent isotypes contributing to the overall affinity of the blood 
group antibodies detected in the SPR analysis used. Isotype 
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FigUre 6 | Binding characteristics of anti-a/B antibodies after immunization with Pn23 vaccine. The percentage of dissociation (a) of blood group 
anti-A/B antibodies before and after immunization with Pneumo 23 Vaccine “Pasteur Merieux” (Pn23) in healthy individuals (n = 28) and in patients with type I DM 
(n = 16) was investigated using the Biacore device, the CM5 chip, and the synthetic blood group specific A/B trisaccharides as described in Section “Materials and 
Methods.” Furthermore, the estimated affinity constant KD (B) of blood group specific anti-A antibodies before and after pneumococcal vaccination were analyzed in 
serum samples of three healthy individuals and two patients with type I DM selected for their initially high anti-A antibody titer (>than 1:256 or >than 700 RU). Kinetic 
measurements of anti-A antibodies binding to surface bound trisaccharide before and after vaccination in two representative individuals (a healthy individual, Ind1, 
and a DM I patient, Ind2) who fulfilled these criteria are given; one healthy individual that was not included in the vaccination protocol but showed high titer for blood 
group anti-A antibodies was measured in parallel (Control). Green curves represent serum sample and red curves serum sample diluted by half; the black curves 
depict the calculated fit. n.d., not detectable.
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bias has been limited since individuals with high blood group 
A IgG but low to undetectable blood group A IgM antibody 
were selected to estimate the binding affinity of anti-A IgG 
antibodies. To determine the affinity (KD) of serum antibod-
ies of a single specificity, isolation and immobilization of the 
respective immunoglobulin clone would be required, which is 
only possible in individuals with monoclonal gammopathy of 
the desired specificity. Interestingly, we did not find a marked 
change in binding characteristics of the cross-reactive blood 
group anti-A/B antibodies, indicating that a relatively small 
increase in IgG antibody titer occurred without additional affin-
ity maturation. An immune response to carbohydrate antigens 
such as to pneumococcal capsular polysaccharide serotypes 1, 
2, 3, 4, 5, 6B, 7, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 
19A, 19F, 20, 22F, 23F, and 33F is thought to be generally TI, 
which can limit the B cell response to the production of IgM 
antibodies mainly and limited amounts of IgG antibodies, and 
the absence of affinity maturation of the rearranged antibody 
genes might lead to the expression of germline sequences of 
antibodies with limited affinity (5, 34, 35). In previous studies, 
the affinity of anti-carbohydrate antibodies for their antigens 
was shown to be 3–5 orders lower in magnitude than affinities 
of anti-protein or anti-peptide antibodies for their antigens (2, 
3, 8, 35). In this study, however, we found no evidence for low 
affinity binding of blood group A/B antibodies obtained either 
from healthy individuals or from patients with type I DM. 
When a mixture of commercially available monoclonal blood 
group anti-A IgM and IgG antibodies was formulated, simulat-
ing the amount and composition of naturally occurring blood 
group anti-A antibodies, the dissociation rate was comparable 
to the serum samples analyzed in Figure 6 (data not shown). 
Germline antibodies recognizing carbohydrate epitopes might 
display significant cross-reactivity because the number of 
potential antigens the immune system must encounter appears 
to extensively outweigh the recombinational potential of the 
germline genes (2, 3, 34, 35). The recombinational potential of 
the germline genes for anti-Gal antibodies specific for blood 
group B substance in unimmunized individuals was shown 
to be limited, because anti-Gal antibodies are encoded by a 
group of 6–8 well-defined and structurally related germline 
progenitors in humans (36). Anti-Gal was shown to be the 
most abundant antibody in humans, constituting approximately 
1% of immunoglobulins and found to be of IgG, IgM, and 
IgA isotype (37, 38). Cryptic antigens capable to bind anti-Gal 
are exposed on senescent human RBCs as well as on RBCs 
of patients with β-thalassemia and sickle cell anemia, but the 
amount of cryptic antigens expressed on RBCs was shown to 
be low (38). The preferential anti-Gal IgG subclass found by 
ELISA was IgG2 using Gal-specific synthetic saccharides, and 
these IgG2 antibodies showed cross-reactivity with blood group 
B antigen (13). ABO blood group antigens were shown to be 
the ideal targets to explore the concomitant effect of muta-
tion on binding affinity and specificity of anti-carbohydrate 
antibodies (33). Mutant anti-carbohydrate antibodies with 
higher affinity achieved by single point mutations of specific 
residues lining the pocket on binding to the A and B blood 
group oligosaccharide antigens showed altered polarity, surface 
complementarity, and side chain aliphatic character, leading 
to improved binding affinity without loss of specificity (33). 
Furthermore, the poly-specificity in germline encoded antibod-
ies to carbohydrate epitopes was shown to be due to greater 
conformational ability in their combining sites, and this flex-
ibility helped to cope with new and changing pathogen surface 
structures by recognizing distinct highly conserved epitopes 
on bacterial polysaccharides (4, 33). Structural analysis of the 
affinity-matured antibody 48G7 and its germline precursor 
antibody showed that the germline precursor could undergo 
an induced fit upon binding to its cognate hapten, while the 
affinity-matured antibody 48G7 displayed lock and key binding. 
An immunological relationship between specific substances of 
ABO and type XIV pneumococcus gave further evidence for 
shared carbohydrate epitopes by showing that adsorption of the 
hemagglutinins in anti-type XIV horse serum with erythrocytes 
of each of the A/B blood groups removed the agglutinins not 
only of that group but also of the other groups (7). In addition 
to pneumococcus, other germs have been shown to cross-react 
with carbohydrate structures on the surface of human cells 
(39–43). The core oligosaccharides of low-molecular-weight 
LPS of pathogenic Neisseria spp. can mimic the carbohydrate 
moieties of glycosphingolipids (40). The core oligosaccharides 
of LPS of Campylobacter jejuni serotypes, which are associated 
with the development of Guillian–Barre’ syndrome, can exhibit 
mimicry of gangliosides (41). Finally, the O-chain of a number 
of Helicobacter pylori strains exhibit mimicry of Lewis(x) and 
Lewis(y) blood group antigens, giving evidence that molecular 
mimicry can serve to camouflage the bacterial surface from 
the host (42).
In conclusion, our study provides evidence for a limited 
carbohydrate epitope sharing between PnPs and blood group 
sugar epitopes in healthy individuals as well as in patients with 
type I DM that could be observed after Pn23 immunization. 
Cross-reactive anti-polysaccharide antibody responses were 
comparable between patients and controls with respect to the 
titer and the affinity. Blood group anti-A/B antibodies are con-
sidered to be naturally occurring antibodies that occur basically 
in any individual with an intact immune response also in the 
absence of antigenic encounter. The clinical relevance of the 
slight increase in blood group anti-A/B IgG isotype response 
in healthy individuals after Pn23 immunization is certainly 
limited; our findings however indicate modulation of anti-A/B 
IgG antibodies, e.g., a booster response during life not only by 
encounter with the genuine antigen such as incompatible blood 
transfusions or alloimmunization during pregnancy but also 
through molecular mimicry of particular carbohydrate epitopes 
shared by blood group AB substances and bacterial polysac-
charides such as PnPs.
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